QuarterHawk — Equity ResearchQuarterHawk — Equity Research

ProQR Therapeutics N.V. (PRQR)

Healthcare

No action
Fundamental
3
Sentiment
4
Technical
2

Do Nothing: liquidity hard block - avgDollarVolume20 $1.08M is far below the $5M floor and recent 3-session dollar volume of about $0.80M is below the $1.5M recent-liquidity floor; both entry types evaluated - a pullback/oversold limit is additionally countertrend (price < SMA50 with MACD < 0) and no breakout stop is supportable at this volume - so no trade is admissible.

Analysis as of 2026-09-30· more than 2 trading days ago

Company overview

ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing RNA-based therapies for genetic disorders. Its key drug candidates, Sepofarsen and Ultevursen, are in Phase II/III trials targeting specific eye conditions. The company also advances its Axiomer RNA base-editing platform and maintains strategic partnerships with institutions like Eli Lilly for developing treatments for genetic conditions.

Fundamental

fair
Fundamental3
Speculative fundamentals

ProQR remains a speculative, catalyst-driven biotech with improved liquidity but weak profitability.

Clinical-stage biotech with refreshed runway after the June 2026 equity financing (including Lilly participation) and minimal debt, but still substantial losses and cash burn (TTM net margin ~−228%, free-cash-flow yield ~−29%). EV/Sales appears low versus many biotech peers, yet profit-based multiples and DCF-style intrinsic value are not reliable at this stage; treat as a speculative, catalyst-driven name rather than a fundamentals-driven compounder.

Sentiment

good
Sentiment4
Catalyst-driven sentiment

Sentiment is positive, driven by recent clinical milestones and supportive media coverage.

Dominant catalyst is the announced first-patient dosing in the Phase 1 AX-0811 cholestatic-liver program (2026-09-09), backed by a forward-dated investor & analyst event on 2026-09-30; media delta is improving (baseline ≈ −0.40 → scoring ≈ +0.28, item-level determinate, moderate confidence) and the Red-Flag Screen is clean with no caps applied; retail chatter is indeterminate.

Technical

weak
Technical2
Bearish trend

Technical indicators show a bearish trend with low liquidity, preventing a viable trade setup.

Chart quality is weak and bounce-only: price 1.66 sits below SMA20 1.86, SMA50 1.94, SMA200 1.76, EMA9 1.73, EMA21 1.84, WMA9 1.69 and WMA21 1.79; only DEMA14 1.65 and TEMA14 1.61 sit just below price. MACD line -0.10 is below its signal -0.07 and both are below zero; ADX14 28.1 is rising while price trades under every major average - a strong DOWN trend read, not a bullish reversal. RSI 32.5 and Williams %R -88.9 are oversold but reflect the slide, with price merely flat-lining 1.62-1.70 for four sessions. Trade disqualifier: liquidity - avgDollarVolume20 about $1.08M is far below the $5M floor, and the recent 3-session regular-session dollar volume of about $0.80M is below the $1.5M recent-liquidity floor; no entry can fill fairly.

You’re looking at 2026-09-30 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.